Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
AstraZeneca
Merck
Johnson and Johnson

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Inotersen sodium - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for inotersen sodium and what is the scope of patent protection?

Inotersen sodium is the generic ingredient in one branded drug marketed by Akcea Theraps and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Inotersen sodium has five hundred and twenty-nine patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for inotersen sodium
International Patents:529
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
DailyMed Link:inotersen sodium at DailyMed
Synonyms for inotersen sodium
1432726-13-0
950736UC77
Inotersen sodium [USAN]
ISIS 420915 salt
UNII-950736UC77

US Patents and Regulatory Information for inotersen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akcea Theraps TEGSEDI inotersen sodium SOLUTION;SUBCUTANEOUS 211172-001 Oct 5, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Akcea Theraps TEGSEDI inotersen sodium SOLUTION;SUBCUTANEOUS 211172-001 Oct 5, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Akcea Theraps TEGSEDI inotersen sodium SOLUTION;SUBCUTANEOUS 211172-001 Oct 5, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Akcea Theraps TEGSEDI inotersen sodium SOLUTION;SUBCUTANEOUS 211172-001 Oct 5, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Akcea Theraps TEGSEDI inotersen sodium SOLUTION;SUBCUTANEOUS 211172-001 Oct 5, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for inotersen sodium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2563920 LUC00096 Luxembourg   Start Trial PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), WHEREIN THE MODIFIED OLIGONUCLEOTIDE COMPRISES: A GAP SEGMENT CONSISTING OF TEN LINKED DEOXYNUCLEOSIDES; A 5' WING SEGMENT CONSISTING OF FIVE LINKED NUCLEOSIDES; AND A 3' WING SEGMENT CONSISTING OF FIVE LINKED NUCLEOSIDES; WHEREIN THE GAP SEGMENT IS POSITIONED BETWEEN THE 5' WING SEGMENT AND THE 3' WING SEGMENT, WHEREIN EACH NUCLEOSIDE OF EACH WING SEGMENT COMPRISES A 2'-O-METHOXYETHYL SUGAR; (...); AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710
2563920 CA 2019 00001 Denmark   Start Trial PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710
2563920 1/2019 Austria   Start Trial PRODUCT NAME: INOTERSEN; REGISTRATION NO/DATE: EU/1/18/1296 (MITTEILUNG) 20180710
2563920 2019C/001 Belgium   Start Trial PRODUCT NAME: UN OLIGONUCLEOTIDE MODIFIE AYANT UNE SEQUENCE CONSTITUEE DE NUCLEOSIDES RELIES TELLE QUE DEFINIE AU BREVET EP-B1-2563920, ET SPECIFIQUEMENT L'INOTERSEN; ET SES DERIVES, TELS QUE SES SELS, EN CE COMPRIS LES SELS SODIQUES; AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710
2563920 PA2019001 Lithuania   Start Trial PRODUCT NAME: INOTERSENAS; REGISTRATION NO/DATE: EU/1/18/1296 20180706
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Merck
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.